Company Number: 15195818

Analysis Date: 2025-07-29 12:34 UTC

1. Industry Classification
   MANGO MEDICAL LTD operates under SIC code 86210, which corresponds to "General medical practice activities." This sector is a subset of the broader healthcare services industry, focused primarily on providing primary care and general practitioner (GP) services. Key characteristics of this sector include a high degree of regulation by health authorities such as the NHS, reliance on patient registrations and appointments, and a business model that often involves contracts with public health systems or private payers. Providers in this sector can range from single-practitioner clinics to larger group practices and healthcare centres.

2. Relative Performance
   As a newly incorporated micro-entity (incorporated October 2023), MANGO MEDICAL LTD is at a very early stage of operations with limited financial history. The latest accounts for the 13-month period ending 31 October 2024 show:

• Current assets of £4,322 versus current liabilities of £5,200, resulting in negative net current assets of £878
• Overall net liabilities of £1,028 and negative shareholder funds of the same amount
• No recorded employees other than the directors themselves, consistent with a startup phase or sole practitioner setup

In comparison, typical micro or small general medical practices often report positive net assets reflecting patient lists, medical equipment, and some working capital. Cash reserves and positive working capital are critical in this sector due to the need for upfront operational costs before reimbursement cycles. The negative net assets here may indicate initial setup costs exceeding immediate income or prepayments not yet realized as revenue. This is not unusual for a startup but highlights the early-stage financial vulnerability compared to established peers.

3. Sector Trends Impact
   The general medical practice sector in the UK is influenced by several prevailing trends:

• Increasing demand for primary care services driven by rising patient populations and chronic disease prevalence
• Growing pressures on NHS contracts and funding models, with some practices diversifying into private services
• Digital transformation including telemedicine and electronic health records enhancing accessibility but requiring upfront investment
• Workforce challenges, including GP shortages and nurse practitioner integration, affecting service capacity
• Regulatory compliance and data security requirements increasing operational complexity and costs

For MANGO MEDICAL LTD, these trends imply a challenging but potentially opportunity-rich environment. As a micro entity, establishing a patient base and managing cash flow carefully will be vital. Adoption of digital tools might offer competitive advantage but also requires capital. The founders’ backgrounds (one director a nurse, the other experienced in management) could support a diversified approach to service delivery.

4. Competitive Positioning
   MANGO MEDICAL LTD currently appears to be a niche player or startup in general medical practice rather than an established leader or follower within the sector. Strengths include:

• Flexibility and agility as a small, new entity to adapt services to local patient needs
• Potential for personalized care given small scale and clinical expertise of directors

Weaknesses or risks compared to typical competitors include:

• Negative net assets indicating a fragile financial base requiring careful management of cash flow and liabilities
• Absence of employees beyond directors, which may limit capacity and scalability in the short term
• Lack of established patient list or contract portfolio, which are key value drivers in this sector
• Limited track record to support negotiation of favorable NHS or private contracts

In comparison, established general medical practices often benefit from longer-term contracts, stable patient registrations, and economies of scale, contributing to positive net assets and stronger working capital positions. MANGO MEDICAL LTD’s current financials suggest it is in the investment and development phase rather than mature operational stage.